Abstract |
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that is characterized by alterations in the balance between effector and regulatory CD4+ T cells. We observed the upregulation of the immune checkpoints (ICs) PD-1 and TIGIT in pathogenic CD4+ T cells during disease progression, and downregulation of their ligands PD-L1 and CD155. Inspired by biomimetic nanotechnology, we fabricated dexamethasone (DXM)-loaded IFN-γ-treated MHC class I deficient cancer membrane-coated nanoparticles (IM-MNPs/DXM) to safely harness the immunosuppressive power of tumor cells for the treatment of SLE. The IM-MNPs inherited the membrane functions, which allowed these particles to evade immune clearance and accumulate in inflammatory organs. The IM-MNPs specifically targeted SLE CD4+ T cells and agonist PD-1/TIGIT signaling to inhibit effector T cell function while enhancing the immunosuppressive function of regulatory T cells (Tregs). The sustained release of DXM inhibited the production of proinflammatory cytokines in the inflammatory microenvironment to further promote Treg-mediated immune homeostasis. The IM-MNPs/DXM showed significant therapeutic efficacy in ameliorating lupus nephritis (LN) and decreasing side effects in vivo. Therefore, the particle represents a promising platform to improve current SLE treatment efficacy while minimizing systemic side effects of DXM and ICs agonist therapy.
|
Authors | Qianqian Guo, Chuanrong Chen, Zhihua Wu, Wei Zhang, Liting Wang, Jian Yu, Longxia Li, Jiali Zhang, Yourong Duan |
Journal | Biomaterials
(Biomaterials)
Vol. 285
Pg. 121517
(06 2022)
ISSN: 1878-5905 [Electronic] Netherlands |
PMID | 35504179
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
Chemical References |
- Programmed Cell Death 1 Receptor
- Receptors, Immunologic
- TIGIT protein, human
- Dexamethasone
|
Topics |
- Dexamethasone
(therapeutic use)
- Humans
- Lupus Erythematosus, Systemic
(drug therapy)
- Lupus Nephritis
- Nanoparticles
- Programmed Cell Death 1 Receptor
- Receptors, Immunologic
- T-Lymphocytes, Regulatory
|